How to diagnose statin-induced myopathy
Presenter: Rodrigo Alonso (ISCP Governor of Chile)
Jul 31, 2024
Individualisation of Antiplatelet Therapy with CY2C19
Presenter: Doreen Tan
Nov 01, 2021
Overview : Why is CYP2C19 polymorphism such a big deal? Clopidogrel requires a two-step activation into the active moiety. CYP2C19 is involved in both steps… more
Single Nucleotide Polymorphisms (SNPs): Role in Precision Medicine
Presenter: Ms Png Wan Yu , Prof Tai E Shyong
Nov 01, 2021
Overview : Single nucleotide polymorphisms, which are called SNPs, and their role in precision medicine. The first of three CLAPs on pharmacogenomics in pharmacotherapy. more
Pharmacogenomics in Cardiology: Focus on Warfarin Genotyping
Presenter: Mr Kim Ji Heon , Prof Goh Boon Cher
Nov 01, 2021
Overview : Pharmacogenomics in cardiology with a focus on warfarin genotyping. Warfarin is most susceptible to genetic polymorphisms that encode for CYP2C9 and VKORC1 enzymes… more
Is Age a Comorbidity which Compels Dose Adjustment with DOACs?
Presenter: Dr Koji Hasegawa , Mr Marvin Sim
Oct 04, 2021
Overview : We will look at the available evidence for the following DOACs that require adjustments due to age. They Apixaban, Dabigatran and Edoxaban. more
Iron Therapy in Heart Failure
Presenter: Dr Louis Teo , Ms Thng Shu Hui
Apr 23, 2021
Overview : Iron deficiency is a common co-morbidity among heart failure patients, with a reported prevalence of between 30% to 50%.Patients can be iron deficient without being anaemic. Iron deficiency diminishes exercise capacity and is associated with poor quality of life s... more
SGLT2 Inhibitors as Leaders in HFrEF?
Presenter: Gheorghe-Andrei Dan , Oh Jing Wen
Apr 22, 2021
Overview : Professor G. Andrei-Dann, Ms Oh Jing Wen and Ms Claire Lew present our two-part overview of SGLT2 Inhibitors as Leaders in HFrEF. Part of our Clap in 60 Seconds series of bite-sized topics. more
One-month Dual Anti-Platelet Therapy (DAPT) in Patients with HBR Undergoing PCI
Presenter: Mark Y Chan
Feb 08, 2021
Overview : Dr Mark Y Chan presents a short introduction to one-month dual anti-platelet therapy (DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). more
Page:
- 1
- 2